However, metformin, known for its inhibition of the mTOR signaling pathway, was suggested to counteract the unfavorable effects of DPP-4 inhibitors on breast cancer metastasis by suppressing mTOR, indicating its potential clinical relevance [78]. This evidence concerns the gene DPP4 and breast carcinoma.